Boston Scientific (NASDAQ: BSX) SEISMIQ Catheter Wins FDA Approval in FRACTURE IDE Trial

Boston Scientific announced that its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter met both primary safety and effectiveness endpoints in the FRACTURE IDE trial, a pivotal study required for US regulatory clearance. The trial success opens a path toward market authorization for the device, which is designed to treat calcified coronary lesions—a common complication in interventional cardiology.

By the Numbers

• SEISMIQ 4CE met primary safety endpoint in FRACTURE IDE trial • SEISMIQ 4CE met primary effectiveness endpoint in FRACTURE IDE trial • Boston Scientific investing $1.5 billion for equity stake in MiRus, a transcatheter aortic valve replacement (TAVR) specialist • $2 billion share buyback authorization announced in conjunction with MiRus investment

Why It Matters

The FRACTURE IDE approval represents a significant regulatory win for Boston Scientific's interventional cardiology portfolio. Coronary calcification is a growing clinical challenge, and lithotripsy devices that can safely debulk or modify plaque enable better stent placement. By achieving both safety and effectiveness endpoints, the SEISMIQ 4CE clears a major hurdle toward 510(k) or de novo clearance from the FDA, potentially adding a new revenue stream to the company's cardiac intervention franchise.

Simultaneously, Boston Scientific's $1.5 billion investment in MiRus underscores its strategic bet on the high-growth TAVR market. MiRus develops transcatheter aortic valve technology, positioning Boston Scientific to compete in a segment that has experienced rapid adoption among patients with severe aortic stenosis. The investment—paired with a $2 billion share repurchase authorization—signals confidence in the company's pipeline and capital allocation strategy.

Wall Street View

Boston Scientific trades at a trailing P/E of 23.7x with a forward P/E of 15.1x, reflecting moderate valuation relative to medical device peers. Net income grew at a 100% earnings growth rate (TTM — may not reflect latest quarter), though revenue expanded at a more measured 11.6% pace year-over-year.

Investor Takeaway

The FRACTURE IDE success de-risks the SEISMIQ commercialization pathway and validates Boston Scientific's investment in calcified lesion solutions. Combined with the strategic MiRus acquisition, the announcements demonstrate disciplined portfolio expansion in high-value interventional segments. Investors should monitor FDA clearance timelines and TAVR adoption metrics as the company executes on both initiatives.